Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System
- PMID: 27217402
- DOI: 10.1161/HYPERTENSIONAHA.115.06892
Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System
Abstract
Apelin peptides mediate beneficial effects on the cardiovascular system and are being targeted as potential new drugs. However, apelin peptides have extremely short biological half-lives, and improved understanding of apelin peptide metabolism may lead to the discovery of biologically stable analogues with therapeutic potential. We examined the ability of angiotensin-converting enzyme 2 (ACE2) to cleave and inactivate pyr-apelin 13 and apelin 17, the dominant apelin peptides. Computer-assisted modeling shows a conserved binding of pyr-apelin 13 and apelin 17 to the ACE2 catalytic site. In ACE2 knockout mice, hypotensive action of pyr-apelin 13 and apelin 17 was potentiated, with a corresponding greater elevation in plasma apelin levels. Similarly, pharmacological inhibition of ACE2 potentiated the vasodepressor action of apelin peptides. Biochemical analysis confirmed that recombinant human ACE2 can cleave pyr-apelin 13 and apelin 17 efficiently, and apelin peptides are degraded slower in ACE2-deficient plasma. The biological relevance of ACE2-mediated proteolytic processing of apelin peptides was further supported by the reduced potency of pyr-apelin 12 and apelin 16 on the activation of signaling pathways and nitric oxide production from endothelial cells. Importantly, although pyr-apelin 13 and apelin 17 rescued contractile function in a myocardial ischemia-reperfusion model, ACE2 cleavage products, pyr-apelin 12 and 16, were devoid of these cardioprotective effects. We designed and synthesized active apelin analogues that were resistant to ACE2-mediated degradation, thereby confirming that stable apelin analogues can be designed as potential drugs. We conclude that ACE2 represents a major negative regulator of apelin action in the vasculature and heart.
Keywords: angiotensin-converting enzyme 2; apelin 17; blood pressure; computer-based model; enzyme kinetics; ischemia reperfusion injury; pyr-apelin 13.
© 2016 American Heart Association, Inc.
Comment in
-
Unlocking the Therapeutic Potential of Apelin.Hypertension. 2016 Aug;68(2):307-9. doi: 10.1161/HYPERTENSIONAHA.116.07057. Epub 2016 May 23. Hypertension. 2016. PMID: 27217400 No abstract available.
Similar articles
-
Apelin is a positive regulator of ACE2 in failing hearts.J Clin Invest. 2013 Dec;123(12):5203-11. doi: 10.1172/JCI69608. Epub 2013 Nov 1. J Clin Invest. 2013. PMID: 24177423 Free PMC article.
-
Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues.J Am Heart Assoc. 2013 Jul 1;2(4):e000249. doi: 10.1161/JAHA.113.000249. J Am Heart Assoc. 2013. PMID: 23817469 Free PMC article.
-
Apelin and ACE2 in cardiovascular disease.Curr Opin Investig Drugs. 2010 Mar;11(3):273-82. Curr Opin Investig Drugs. 2010. PMID: 20178040 Review.
-
Prolyl Carboxypeptidase Mediates the C-Terminal Cleavage of (Pyr)-Apelin-13 in Human Umbilical Vein and Aortic Endothelial Cells.Int J Mol Sci. 2021 Jun 22;22(13):6698. doi: 10.3390/ijms22136698. Int J Mol Sci. 2021. PMID: 34206648 Free PMC article.
-
Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications.Clin Sci (Lond). 2020 Sep 18;134(17):2319-2336. doi: 10.1042/CS20200479. Clin Sci (Lond). 2020. PMID: 32901821 Review.
Cited by
-
Agri-Food Extracts Effectiveness in Improving Antibacterial and Antiviral Properties of Face Masks: A Proof-of-Concept Study.ChemistrySelect. 2021 Mar 5;6(9):2288-2297. doi: 10.1002/slct.202004678. Epub 2021 Mar 2. ChemistrySelect. 2021. PMID: 33821214 Free PMC article.
-
Molecular Analysis of Hot-Spot Regions of ACE2 and TMPRSS2 in SARS-CoV-2 "Invulnerable" Individuals.Cureus. 2023 Aug 11;15(8):e43344. doi: 10.7759/cureus.43344. eCollection 2023 Aug. Cureus. 2023. PMID: 37700940 Free PMC article.
-
The renin-angiotensin system: going beyond the classical paradigms.Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H958-H970. doi: 10.1152/ajpheart.00723.2018. Epub 2019 Feb 1. Am J Physiol Heart Circ Physiol. 2019. PMID: 30707614 Free PMC article. Review.
-
Correlation Between Apelin and Collateral Circulation in Patients with Middle Cerebral Artery Occlusion and Moyamoya Disease.Int J Gen Med. 2022 Jan 19;15:699-709. doi: 10.2147/IJGM.S341015. eCollection 2022. Int J Gen Med. 2022. PMID: 35082519 Free PMC article.
-
Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system.Ann Transl Med. 2020 Mar;8(5):243. doi: 10.21037/atm.2020.02.07. Ann Transl Med. 2020. PMID: 32309390 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases